Pathology Research International

Research Article

Rosiglitazone-Mediated Effects on Skeletal Muscle Gene Expression Correlate with Improvements in Insulin Sensitivity in Individuals with HIV-Insulin Resistance

Table 2

Gene expression in muscle tissue of insulin-resistant HIV infected subjects before and after treatment with rosiglitazone.
Before rosiAfter rosiFold change 𝑃 value
( × 1 0 − 4 )( × 1 0 − 4 )
LPL 2 4 . 7 ± 2 . 8 3 0 . 2 ± 4 . 8 1 . 2 7 ± 0 . 1 6 NS
CPT-1 5 7 . 6 ± 5 . 3 4 4 . 7 ± 4 . 3 0 . 8 1 ± 0 . 0 8 .018
PPARγ 0 . 9 5 4 ± 0 . 1 7 7 0 . 9 4 2 ± 0 . 1 8 5 1 . 1 2 ± 0 . 2 1 NS
ACPR30 4 . 1 4 ± 2 . 1 5 . 1 3 ± 2 . 6 1 . 7 6 ± 0 . 5 8 NS
SCD 1 6 . 3 ± 7 . 2 2 5 . 3 ± 9 . 6 1 . 6 7 ± 0 . 2 7 .03
PPARα 3 4 . 5 ± 6 . 2 3 5 . 2 ± 5 . 0 1 . 1 7 ± 0 . 1 4 NS
All gene expression data before and after treatment with rosiglitazone (8 mg/d for 12 weeks) are expressed as means ± SEM and normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). LPL: lipoprotein lipase; CPT-1: carnitine palmitoyl transferase-1; PPARγ: peroxisome proliferator-activated receptor γ; ACPR30: Adiponectin; SCD: steroyl CoA-desaturase; and PPARα: peroxisome proliferator-activated receptor α. Statistical significance was determined with a paired 𝑡 -test (SPSS).